Biostax Corp (BTAX)

[goforthebet]

I want to see some development as well, but I give them still a credit. I do think, that Mr. Phelps is not rising his very good reputation playing games. He needs more time to get things going. I still hope so..

Kevin J Phelps

https://www.globenewswire.com/en/news-release/2019/01/09/1683002/0/en/Immune-Therapeutics-welcomes-Kevin-Phelps-to-Board-of-Directors.html

Kevin Phelps is a finance and business development professional who has spent his career determining, satisfying and managing the operational needs of a wide range of companies. With greater than 25 years of broad, professional corporate experience, Mr. Phelps has held senior management positions, successfully raising capital for startup companies, managing financial organizations and developing new businesses through technology, strategic alliances and acquisition projects.

Mr. Phelps is a General Partner in Trillium Group, LLC, a Rochester, New York based venture capital firm and a Founder of Cashel Rock Advisors and FinanciaLink Strategic Alliances, two private wealth management firms specializing in strategies for corporations and high net-worth individuals.

His professional experience began as a CPA with Price Waterhouse (now PwC), where he consulted with over 20 companies with a principal focus on emerging growth opportunities. In 1987, he was recruited to head financial planning for Eastman Kodak’s BioProducts Division. He assisted in the spinoff of the business into an international joint venture and became the Chief Financial Officer of the new entity, Genencor International, Inc. In this role, he created and managed Genencor’s finance and treasury groups and established the company’s accounting and reporting practices. He raised in excess of $100 million in debt capital to fund Genencor’s operations and expansion. He also served as Vice President of New Business Development.

“We are very pleased to welcome Mr. Phelps to our Board of Directors. His extensive experience as a finance specialist, along with his deep knowledge of business development and operations, will assist the company in moving to the forefront of specialized pharmaceuticals,” stated Noreen Griffin, President and CEO of Immune Therapeutics, Inc.

“I am excited to join Immune Therapeutics’ Board of Directors and to contribute my experience in entrepreneurial ventures. Immune Therapeutics has great potential, and I intend to assist in maximizing this potential to bring unprecedented ROI for investors,” said Mr. Phelps.

“I look forward to working with Mr. Phelps. Mr. Phelps’s proven leadership in business and finance make him an excellent addition to IMUN’s Board,” stated Dr. Roscoe Moore, Chairman of Immune Therapeutics’ Board of Directors, member of the company’s Scientific Advisory Board, and Former United States Assistant Surgeon General.